FasL (human) (multimeric) (rec.)

AdipoGen Life Sciences

FasL (human) (multimeric) (rec.)

10

Research Use Only

0.1 mg/ml

>95%

FASLG

Fas ligand

ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L, FASL, TNFSF6, TNLG1A, tumor necrosis factor ligand superfamily member 6, CD95 ligand, Fas ligand (TNF superfamily, member 6), apoptosis (APO-1) antigen ligand 1, apoptosis antigen ligand, fas antigen ligand, mutant tumor necrosis factor family member 6, tumor necrosis factor ligand 1A

Tumor necrosis factor ligand superfamily member 6

MultimericFasL™ is a high activity construct in which two trimeric FasL are artificially linked via the collagen domain of ACRP30. This construct very effectively mimics the natural membrane-assisted aggregation of FasL in vivo. FasL is a cytokine that binds to TNFRSF6/Fas, a receptor that transduces the apoptotic signal into cells. It is involved in cytotoxic T cell mediated apoptosis and in T cell development. FasL treatment of stem cells is a robust method for proliferating cells in culture while improving their stemness properties. Treatment with FasL results in a large quantity of Adipose Derived Stem Cells (ASC) of high quality. - Protein. Human FasL (aa 139-281) is fused at the N-terminus to mouse ACRP30headless (aa 18-111) and a FLAG®-tag. Source: HEK 293 cells. Endotoxin content: 95% (SDS-PAGE). MultimericFasL™ is a high activity construct in which two trimeric FasL are artificially linked via the collagen domain of ACRP30. This construct very effectively mimics the natural membrane-assisted aggregation of FasL in vivo. FasL is a cytokine that binds to TNFRSF6/Fas, a receptor that transduces the apoptotic signal into cells. It is involved in cytotoxic T cell mediated apoptosis and in T cell development.

-20°C,2°C to 8°C

41116100

Human